ישראל -
עברית -
Ministry of Health
systems for warming and saving patient's heat
בפקס בע"מ - אחות - לשימוש בחדר ניתוח, מח' פגים, תינוקיות ויילודים
ישראל -
עברית -
Ministry of Health
ambu lifesaving equipment + accessories
פרומדיקו בע"מ - רופא - הרדמה/טיפול נמרץ/טראומה - ציוד להצלת חיים + נלווים
ישראל -
עברית -
Ministry of Health
אקטיק 200 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
ישראל -
עברית -
Ministry of Health
אקטיק 600 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
ישראל -
עברית -
Ministry of Health
אקטיק 1200 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
ישראל -
עברית -
Ministry of Health
דיפרוספאן זריקה
organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.
ישראל -
עברית -
Ministry of Health
mguard prime
inspire md ltd - רופא - mguard prime coronary stent system is indicated for improving luminal diameter in vessels with reference diameter from 2.5 to 4.0 mm having lesion length <38 mm and providing embolic protection in the following cases: • symptomatic coronary artery disease due to discrete de novo or restenotic lesion in native coronary artery. • symptomatic coronary artery disease due to culprit lesion in saphenous vein graft • treatment of coronary lesion in patients undergoing primary or rescue pci for acute st-segment elevation myocardial infarction(stemi) • treatment of coronary lesion having atherothrombotic appearance in patients with non st-elevation acute coronary syndromes (unstable angina and non st-segment elevation myocardial infarction).